{"mainPropery":{"diseaseId":10455,"diseaseName":"Familial pulmonary arterial hypertension leucopenia and atrial septal defect","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/10455/familial-pulmonary-arterial-hypertension-leucopenia-and-atrial-septal-defect","synonyms":["Familial pulmonary arterial hypertension, leucopenia and ASD","Familial PAH, leucopenia and ASD"],"synonyms-with-source":[{"name":"Familial pulmonary arterial hypertension, leucopenia and ASD"},{"name":"Familial PAH, leucopenia and ASD"}],"identifiers":[]},"diseaseCategories":[],"organizations":[],"resource descriptions":[],"overviewQuestion":{"questionId":0,"dateModified":"0001-01-01T00:00:00"},"basicQuestions":[],"references":[],"relatedDiseases":[],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[{"productId":634,"genericName":"Selexipag","tradeName":"Uptravi","tradeLink":"https://www.uptravi.com/","manufacturer":"","sponsor":"Actelion Ltd","indication":"For use of Uptravi (Selexipag) Tablets, 200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg for treatment of pulmonary arterial hypertension (PAH, WHO Group I) to reduce the risks of disease progression and hospitalization for PAH.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=UPTRAVI","medlinePlusLink":""}],"EncodedName":"Familial_pulmonary_arterial_hypertension_leucopenia_and_atrial_septal_defect"}